NASDAQ:WMGI - Wright Medical Group Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $30.00
  • Forecasted Upside: 0.07 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$29.98
+0.30 (1.20%)
Get New Wright Medical Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WMGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WMGI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$30.00
▲ +0.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Wright Medical Group in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a 0.07% upside from the last price of $29.98.
Hold
The current consensus among 2 polled investment analysts is to hold stock in Wright Medical Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 11 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 11 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 11 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2020Stifel NicolausDowngradeBuy ➝ Hold$30.00Low
i
7/29/2020Needham & Company LLCReiterated RatingHoldLow
i
Rating by Michael Matson at Needham & Company LLC
3/13/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
i
12/23/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$30.75N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
12/6/2019Wells Fargo & CompanyReiterated RatingHoldLow
i
Rating by Larry Biegelsen at Wells Fargo & Company
11/27/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by Richard Newitter at SVB Leerink LLC
11/18/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by R. Newitter at SVB Leerink LLC
11/15/2019Needham & Company LLCLower Price TargetBuy$32.00 ➝ $30.75Low
i
11/12/2019Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
i
11/12/2019Northcoast ResearchDowngradeBuy ➝ NeutralLow
i
Rating by D. Keiser at Northcoast Research
11/11/2019Wells Fargo & CompanyReiterated RatingHoldLow
i
Rating by Larry Biegelsen at Wells Fargo & Company
11/11/2019Robert W. BairdDowngradeOutperform ➝ Neutral$28.00 ➝ $31.00Low
i
11/4/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralMedium
i
Rating by C. Bijou at Cantor Fitzgerald
11/4/2019Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
i
Rating by Matthew O'Brien at Piper Jaffray Companies
8/16/2019Piper Jaffray CompaniesSet Price TargetBuy$27.00Low
i
Rating by Matthew O'Brien at Piper Jaffray Companies
8/12/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$28.00 ➝ $23.00Medium
i
8/9/2019Bank of AmericaDowngradeBuy ➝ Neutral$25.00Low
i
8/8/2019OppenheimerLower Price TargetOutperform$34.00 ➝ $29.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/8/2019Credit Suisse GroupLower Price TargetOutperform$34.00 ➝ $30.00Low
i
8/8/2019BMO Capital MarketsLower Price TargetOutperform$36.00 ➝ $30.00High
i
8/8/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$34.00 ➝ $24.00High
i
7/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $33.00Low
i
5/8/2019OppenheimerSet Price TargetHold$34.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
4/10/2019Needham & Company LLCReiterated RatingBuy$38.00Low
i
3/14/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $36.00Medium
i
3/11/2019Wells Fargo & CompanyReiterated RatingBuyMedium
i
2/27/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $34.00High
i
2/27/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
2/27/2019Jefferies Financial GroupBoost Price TargetBuy$40.00Medium
i
2/27/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00 ➝ $38.00High
i
1/14/2019Cantor FitzgeraldSet Price TargetBuy$35.00Medium
i
Rating by Craig Bijou at Cantor Fitzgerald
1/7/2019Needham & Company LLCReiterated RatingBuy$35.00High
i
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$33.00Low
i
12/10/2018Cantor FitzgeraldReiterated RatingBuy$35.00Medium
i
11/28/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$31.00Low
i
11/8/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $35.00Medium
i
11/8/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$31.00 ➝ $35.00Medium
i
11/8/2018Piper Jaffray CompaniesBoost Price TargetOverweight$35.00Medium
i
11/8/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.00Medium
i
11/8/2018OppenheimerSet Price TargetHold$30.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/25/2018Needham & Company LLCBoost Price TargetBuy$30.00 ➝ $35.00High
i
8/29/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$28.00 ➝ $31.00Medium
i
8/28/2018Needham & Company LLCUpgradeHold ➝ Buy$30.00High
i
8/21/2018Stifel NicolausInitiated CoverageBuy$34.00High
i
Rating by Mathew Blackman at Stifel Nicolaus
8/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$32.00High
i
8/9/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.00High
i
8/9/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$28.00 ➝ $30.00High
i
8/9/2018Bank of AmericaUpgradeNeutral ➝ Buy$28.00 ➝ $34.00Low
i
8/9/2018OppenheimerSet Price TargetHold$28.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/9/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $35.00High
i
7/10/2018BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$25.00 ➝ $25.00Low
i
6/21/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $32.00High
i
6/13/2018GuggenheimUpgradeNeutral ➝ BuyHigh
i
5/10/2018OppenheimerSet Price TargetHold$25.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$28.00 ➝ $25.00High
i
2/28/2018BarclaysReiterated RatingOverweight ➝ Overweight$27.00 ➝ $25.00Low
i
2/28/2018OppenheimerSet Price TargetHold$25.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/8/2018Cantor FitzgeraldSet Price TargetBuy$30.00Medium
i
Rating by Craig Bijou at Cantor Fitzgerald
1/5/2018Cantor FitzgeraldReiterated RatingOverweight ➝ OverweightHigh
i
11/3/2017Jefferies Financial GroupReiterated RatingBuyN/A
i
11/2/2017Royal Bank of CanadaReiterated RatingBuy$30.00N/A
i
11/2/2017BarclaysLower Price TargetOverweight$33.00 ➝ $30.00N/A
i
11/2/2017BMO Capital MarketsLower Price TargetOutperform$34.00 ➝ $31.00N/A
i
11/2/2017Needham & Company LLCReiterated RatingHoldN/A
i
10/12/2017Jefferies Financial GroupReiterated RatingBuy$33.00N/A
i
10/6/2017Robert W. BairdReiterated RatingBuy$33.00N/A
i
10/3/2017Royal Bank of CanadaReiterated RatingBuy$31.00Low
i
9/1/2017Needham & Company LLCReiterated RatingHoldLow
i
8/4/2017Jefferies Financial GroupReiterated RatingBuy$33.00High
i
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$34.00High
i
8/3/2017OppenheimerSet Price TargetHold$29.00 ➝ $30.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$33.00Medium
i
5/4/2017OppenheimerSet Price TargetHold$29.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/4/2017Jefferies Financial GroupBoost Price TargetBuy$30.00 ➝ $33.00Medium
i
5/4/2017BMO Capital MarketsReiterated RatingBuy$34.00High
i
5/4/2017Needham & Company LLCReiterated RatingHoldHigh
i
4/24/2017Jefferies Financial GroupReiterated RatingBuyLow
i
4/11/2017Bank of AmericaDowngradeBuy ➝ NeutralHigh
i
3/21/2017Northcoast ResearchUpgradeNeutral ➝ Buy$36.00Medium
i
Rating by D. Keiser at Northcoast Research
2/22/2017Needham & Company LLCReiterated RatingHoldN/A
i
2/22/2017Jefferies Financial GroupReiterated RatingBuy$30.00N/A
i
2/22/2017BMO Capital MarketsBoost Price TargetBuy$31.00N/A
i
2/15/2017Needham & Company LLCDowngradeBuy ➝ HoldN/A
i
1/3/2017GuggenheimDowngradeBuy ➝ NeutralN/A
i
11/3/2016BarclaysReiterated RatingBuy$33.00N/A
i
11/3/2016SVB LeerinkReiterated RatingOutperform$27.00 ➝ $25.00N/A
i
9/28/2016BarclaysReiterated RatingOverweight$33.00N/A
i
8/15/2016Jefferies Financial GroupReiterated RatingBuy$29.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
8/3/2016SVB LeerinkReiterated RatingOutperform$25.00 ➝ $27.00N/A
i
8/3/2016JPMorgan Chase & Co.Set Price TargetBuy$26.00N/A
i
Rating by Andrew Hanover at JPMorgan Chase & Co.
8/3/2016UBS GroupLower Price TargetBuy$30.00 ➝ $28.00N/A
i
7/13/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $26.00N/A
i
7/13/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$23.00N/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
7/12/2016SVB LeerinkReiterated RatingOutperform$25.00N/A
i
7/11/2016Needham & Company LLCReiterated RatingBuy$24.00N/A
i
Rating by Michael Matson at Needham & Company LLC
6/18/2016UBS GroupReiterated RatingBuy$30.00N/A
i
6/8/2016GuggenheimInitiated CoverageBuy$22.00N/A
i
5/16/2016Robert W. BairdReiterated RatingBuyN/A
i
5/14/2016Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Michael Matson at Needham & Company LLC
5/5/2016Jefferies Financial GroupReiterated RatingBuy$29.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/5/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
i
5/5/2016SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $25.00N/A
i
5/5/2016Needham & Company LLCBoost Price TargetBuy$22.00 ➝ $24.00N/A
i
(Data available from 4/22/2016 forward)
Wright Medical Group logo
Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth. It also provides sports medicines and other products to mechanically repair tissue-to-tissue or tissue-to-bone injuries, as well as other ancillary products. The company offers its products to orthopedic, trauma, and podiatric surgeons. It markets and sells its products through direct sales representatives, independent sales agencies, direct sales offices, and distributors. The company was founded in 1999 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $29.98
$29.98
$29.98

50 Day Range

MA: $30.23
$29.98
$30.72

52 Week Range

Now: $29.98
$23.14
$30.74

Volume

9,689 shs

Average Volume

2,015,203 shs

Market Capitalization

$3.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Wright Medical Group?

The following Wall Street sell-side analysts have issued stock ratings on Wright Medical Group in the last twelve months: Needham & Company LLC, Stifel Nicolaus, and TheStreet.
View the latest analyst ratings for WMGI.

What is the current price target for Wright Medical Group?

1 Wall Street analysts have set twelve-month price targets for Wright Medical Group in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 0.1%. Stifel Nicolaus has the highest price target set, predicting WMGI will reach $30.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $30.00 for Wright Medical Group in the next year.
View the latest price targets for WMGI.

What is the current consensus analyst rating for Wright Medical Group?

Wright Medical Group currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in WMGI, but not buy more shares or sell existing shares.
View the latest ratings for WMGI.

What other companies compete with Wright Medical Group?

How do I contact Wright Medical Group's investor relations team?

Wright Medical Group's physical mailing address is PRINS BERNHARDPLEIN 200, AMSTERDAM P7, 38117. The medical device company's listed phone number is 31-20-521-4777 and its investor relations email address is [email protected] The official website for Wright Medical Group is www.wright.com.